BCAL Diagnostics secures extra A$4.9m to fund cancer detection portfolio
BCAL Diagnostics (ASX:BDX), an Australian healthcare company focused on early cancer detection, has secured firm commitments for a further A$4.9 million under its existing A$10 million convertible note facility, with the additional funds to be drawn down as required.

_1429929_640x360_2505052739794-640x360.webp&w=3840&q=75)
_1429914_640x360_2505050179647-640x360.webp&w=3840&q=75)


_1429897_640x360_2505049155848-640x360.webp&w=3840&q=75)
_1429899_640x360_2505052739570-640x360.webp&w=3840&q=75)




